Dr. Reddy's Laboratories faces legal action in the United States

Dr. Reddy's Laboratories, Inc., a wholly-owned step-down subsidiary of Dr. Reddy's Laboratories Limited, has found itself among several pharmaceutical companies named as defendants in a complaint filed on October 6, 2023. The complaint was lodged in the United States District Court for the Northern District of California by Mayo Clinic and Lifepoint Corporate Services.

 

The complaint alleges violations of federal and state antitrust laws, as well as other state laws, asserting that the defendants engaged in improper competition restraint and maintained a shared monopoly in the sale of brand and generic Revlimid through settlements of patent litigation. According to the complaint, these agreements resulted in an improper delay of generic entry until 2022 and then limited generic competition through 2026.

 

In response to these allegations, Dr. Reddy's Laboratories has stated that it believes the claims lack merit and has vowed to vigorously defend itself against the litigation.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

14 mins read . 06 Dec 2024

Stocks Under 1000 Rupees in India

  • 0 people read
blog-logo

Economy

blog-logo

8 mins read . 05 Dec 2024

History of Reliance Group

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions